Stem Cell Analysis, Omics (Including Immunomics) and Artificial Intelligence in Glioblastoma

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

February 29, 2024

Primary Completion Date

May 30, 2026

Study Completion Date

December 30, 2026

Conditions
Glioblastoma, IDH-wildtype
Interventions
OTHER

Biological biomarker analysis

Collection of tumor and blood samples at T0 (surgery) and T1 (6 months follow-up) Tumor microenvironment and blood multi-omics analysis In-depth functional characterization of tumor microenvironment Cancer stem cells generation and drug testing Data integration by business intelligence and development of AI-based prognostic markers

Trial Locations (1)

00168

RECRUITING

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Oslo University Hospital

OTHER

collaborator

Istituto Superiore di Sanità

OTHER

collaborator

Luxembourg Institute of Health

OTHER_GOV

collaborator

Hospital Donostia

OTHER

collaborator

University Medical Center Goettingen

OTHER

collaborator

National Research Council

UNKNOWN

lead

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

OTHER